Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 in Stage IV Breast Cancer
NCT00083278Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in Adenocarcinoma of the Breast, sponsored by Bristol Myers Squibb. Primary endpoint: Initial Antitumor Activity Profile. Started May 2003; status: completed.
02
Drugs
ipilimumab
03
Conditions
Adenocarcinoma of the Breast
Beyond the preview
Go deeper on NCT00083278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083278.